BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

GlaxoSmithKline

Kadmon Hlds

Novo Nordisk

Pfizer

Sanofi

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

BioNTech has been a phenomenal success story for investors, delivering a ~1,900% gain on investment since its 2019 IPO. Sales of its mRNA vaccine Comirnaty will earn the company in excess of $18bn in 2021, management believes - firmly ahead of expectations.

BioNTech: Stock Price Buoyancy Depends On Comirnaty Sales, But Long Term Value On Pipeline

Dr. Özlem Türeci said she could imagine a scenario in which booster shots were given every 12-18 months, but added that more data were needed.

BioNTech Co-Founder Says Covid Will ‘Become Manageable' and Be Around for Years

The co-founder and chief medical officer of BioNTech, the German firm which developed a Covid-19 vaccine alongside Pfizer, told CNBC that the world "should not live in fear" of the virus.

'Covid will become manageable': BioNTech co-founder says the virus will be with us for years

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $277.44, marking a +0.33% move from the previous day.

BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

BioNTech, a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the last month. This compares to the S&P 500 which was up about 2% over the last week.

What's New With BioNTech Stock?

Moderna

Novavax

Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Today

Pfizer Inc. PFE, -0.84% and German partner BioNTech SE BNTX, -7.91% said Tuesday they have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, and are seeking an emergency-use authorization to add that patient group to the program. The news comes after the companies released initial data from the trial last week, saying the vaccine had proved safe and effective.

Pfizer and BioNTech seek FDA authorization for vaccination of 5- to 11-year-olds

Pfizer Inc. PFE, -0.84% and German partner BioNTech SE BNTX, -7.91% said Tuesday they have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, and are seeking an Emergency Use Authorization to add that patient group to the program. The news comes after the companies released initial data from the trial last week, saying the vaccine had proved safe and effective.

Pfizer and BioNTech submit initial data to FDA from trial of COVID-19 vaccine in children aged 5 to 12

NEW YORK and MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in children 5 to

Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to

IDEXX Laboratories

MercadoLibre

Atlassian

None of it has anything to do with business fundamentals.

Why Are the Nasdaq's Top Growth Stocks Freaking Out Monday?

Shares of COVID-19 vaccine makers, including BioNTech SE - ADR (NASDAQ: BNTX), are trading lower amid continued volatility in the space as investors weigh booster shot progress. Pfizer CEO Albert Bourla recently predicted a return to 'normal life' within a year with a likely need for annual shots.

Why BioNTech Shares Are Falling

Volatility remains high among vaccine stocks as two CEOs predict the end of the pandemic next year.

Why BioNTech, Moderna, and Novavax Stocks Are Sliding Today

The decision is in line with FDA authorization for booster shots of the Pfizer-BioNTech vaccine.

CDC director endorses Pfizer booster for frontline workers, overruling advisory panel

The Centers for Disease Control and Prevention (CDC) backed a booster shot of Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine for Americans aged 65 and older and adults with an underlying medical condition. It also said that residents of nursing homes and other long-term-care facilities should also get the extra shots.

Pfizer/BioNTech COVID-19 Boosters For Seniors, Certain Vulnerable Adults Coming Soon - CDC Panel Recommends

Dr. Rochelle Walensky recommended workers in high-risk settings to also be offered Pfizer Covid booster doses, despite the CDC advisers voting against this group getting the third shot.

CDC Director Backs Pfizer Booster Shots For Seniors, Vulnerable—And High-Risk Workers

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.

Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?

An advisory committee to the agency rejected a recommendation for boosters for people aged 18 to 64 in an occupational or institutional setting where the risk of transmission is high.

CDC Advisors Recommend Pfizer Booster Shots for Older Americans

A panel advising the CDC poured over new data on vaccines this week before recommending boosters for adults aged 65+, but against shots for workers.

CDC advisors voted in favor of Pfizer boosters for older Americans - but against extra shots for healthcare workers, in a major break with the FDA

With its latest ruling on the biotech's coronavirus vaccine, the FDA boosts the investment case for the stock.

Why BioNTech Thrashed the Market on Thursday

Pfizer recipients 65 and older and those living in long-term care facilities would be eligible for a booster. People ages 18 to 64 with an underlying health condition would be eligible too.

CDC panel recommends Pfizer booster for some people

A key CDC advisory group voted to recommend distributing Pfizer and BioNTech's Covid-19 booster shots to older Americans and other vulnerable people.

CDC panel endorses Pfizer Covid booster shots for people 65 and older

The European Medicines Agency (EMA) expects to decide on the authorization for Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 booster shot at the beginning of October, Reuters reported citing a source directly familiar with the matter. The European decision will follow the FDA authorization granted for the additional dose of the vaccine for certain populations.

EMA To Decide On Pfizer/BioNTech COVID-19 Booster Next Month: Reuters

The U.S. Food and Drug Administration on Wednesday authorized a booster dose of the Pfizer Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine for people aged 65 years and older as well as other high-risk Americans. What Happened: The FDA said that the booster dose can be administered to individuals that meet these criteria six months after completion of their first two doses.

Pfizer COVID-19 Vaccine Booster Shot Approved By FDA For High-Risk Individuals, People 65 And Up

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high ris

News for BioNTech SE Stock (BNTX)